222 related articles for article (PubMed ID: 3515679)
21. Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients.
Benvenisty AI; Tannenbaum GA; Cohen DJ; Appel G; Hardy MA
Transplant Proc; 1987 Feb; 19(1 Pt 3):1889-91. PubMed ID: 3274446
[No Abstract] [Full Text] [Related]
22. Minnesota experience with 81 pancreas transplants since 1978.
Sutherland DE; Chinn PL; Goetz FC; Elick BA; Najarian JS
Transplant Proc; 1984 Jun; 16(3):695-703. PubMed ID: 6375036
[No Abstract] [Full Text] [Related]
23. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus.
Boudreaux JP; McHugh L; Canafax DM; Asher N; Sutherland DE; Payne W; Simmons RL; Najarian JS; Fryd DS
Transplant Proc; 1987 Feb; 19(1 Pt 2):1811-3. PubMed ID: 3079040
[No Abstract] [Full Text] [Related]
25. The use of triple therapy to minimize cyclosporine (CsA) nephrotoxicity in renal transplantation.
Landsberg DN; Rae A; Chiu A; Werb R; Taylor P; Chan-Yan C; Manson AD
Transplant Proc; 1989 Feb; 21(1 Pt 2):1550-1. PubMed ID: 2652502
[No Abstract] [Full Text] [Related]
26. Control of rejection of transplanted organs.
Keown PA; Stiller CR
Adv Intern Med; 1986; 31():17-46. PubMed ID: 3511616
[No Abstract] [Full Text] [Related]
27. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping.
Stuart FP; Stuart JK; Thistlethwaite JR; Gaber AO; Mayes J
Transplant Proc; 1987 Feb; 19(1 Pt 3):1959-60. PubMed ID: 3152656
[No Abstract] [Full Text] [Related]
28. The role of antilymphocyte globulin in cadaver renal transplantation.
Novick AC
Transplant Proc; 1986 Jun; 18(3 Suppl 2):22-7. PubMed ID: 3521000
[No Abstract] [Full Text] [Related]
29. High long-term graft survival rates in kidney transplantation with the sequential association of antithymocyte globulin and cyclosporine A monotherapy.
Hourmant M; Buzelin F; Dubigeon P; Soulillou JP
Transplant Proc; 1987 Feb; 19(1 Pt 3):2113-4. PubMed ID: 3079073
[No Abstract] [Full Text] [Related]
30. Effect of early cyclosporine levels on kidney allograft rejection.
Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine nephrotoxicity and the consequences of conversion to azathioprine.
Chapman JR; Morris PJ
Transplant Proc; 1985 Aug; 17(4 Suppl 1):254-60. PubMed ID: 3895664
[No Abstract] [Full Text] [Related]
32. Two-year fate of 100 kidney transplants treated with low-dose cyclosporine without biopsy guidelines.
Civati G; Del Favero E; Brando B; Broggi ML; Busnach G; Forti D; Belli L; Minetti L
Transplant Proc; 1987 Feb; 19(1 Pt 3):1856-7. PubMed ID: 3079051
[No Abstract] [Full Text] [Related]
33. Quadruple drug induction treatment in patients with ATN-kidneys: expensive but effective.
Schilling M; Schleibner S; Abendroth D; Illner WD; Schneeberger H; Land W
Transplant Proc; 1990 Oct; 22(5):2283. PubMed ID: 2219369
[No Abstract] [Full Text] [Related]
34. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
35. Has cyclosporine really relegated pretransplant blood transfusions to therapeutic obsolescence?
Melzer JS; Husing RM; Feduska NJ; Tomlanovich SJ; Vincenti F; Amend WJ; Garovoy M; Salvatierra O
Transplant Proc; 1987 Feb; 19(1 Pt 3):1971-3. PubMed ID: 2856274
[No Abstract] [Full Text] [Related]
36. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
Canafax DM; Savik SK; Draxler CA; Le CT; Ascher NL; Payne WD; Sutherland DE; Migliori RJ; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
[No Abstract] [Full Text] [Related]
37. Conversion of cyclosporine to azathioprine in renal transplant patients.
Shen SY; Zemel SM; Weir MR; Dagher FJ; Bentley FR
Transplant Proc; 1987 Feb; 19(1 Pt 3):2032-6. PubMed ID: 3547906
[No Abstract] [Full Text] [Related]
38. Conversion from cyclosporine to azathioprine in renal graft recipients.
MacDonald AS; Belitsky P; Gupta R; Bitter-Suermann H; Campbell R; Cohen A; Lannon SG
Transplant Proc; 1985 Aug; 17(4):1940-2. PubMed ID: 3895634
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of cyclosporine compared with azathioprine in cadaveric renal transplantation.
Henry ML; Sommer BG; Ferguson RM
Am J Surg; 1985 Nov; 150(5):533-6. PubMed ID: 2998215
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation.
First MR; Smith RD; Weiss MA; Schroeder TJ; Kant KS; Munda R; Stephens GW; Penn I; Alexander JW
Transplant Proc; 1989 Feb; 21(1 Pt 2):1567-70. PubMed ID: 2652509
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
